Shares of Zimmer Biomet (ZBH) were under pressure on Monday after cutting its full-year forecast. The medical-device maker lowered its 2016 revenue outlook to between $7.63 billion and $7.65 billion, that's below the company's previous guidance. Zimmer Biomet also expects full-year earnings between $7.90 and $7.95 a share, reducing the high end of its previous outlook. For the third quarter, the company reported earnings of $1.79 a share, which was in line with Wall Street's expectations. But revenue of $1.83 billion for the period was slightly below estimates.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.